Clinical Trial

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

With 12% weight loss in a pivotal trial, Vincentage Pharma's VCT220 pill is set to challenge injectables and reshape China's obesity drug market.

With a new CEO who led a startup to FDA approval and acquisition, VahatiCor aims to commercialize its novel A-FLUX system for millions with chronic chest pain.

New data reveals TARA-002 has a 55% complete response rate at one year for NMIBC, offering a promising, safer alternative to standard care.

A new oral drug for depression shows rapid, robust effects in a key trial, offering hope for millions by targeting a different brain pathway.

The biotech firm is set to launch its first commercial products, using an innovative strategy to tackle long-neglected markets in women's healthcare.

A new Tysons wellness center promises stronger bones in just 10 minutes a week, but its high-tech claims are facing scrutiny from the scientific community.

With a new CFO known for big-ticket financing and IPO readiness, clinical-stage OnCusp Therapeutics is gearing up for its next major growth spurt.

A landmark clinical trial shows umbilical cord blood can safely reduce debilitating back pain, opening a new frontier beyond traditional stem cell uses.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

With a new CEO, a half-billion-dollar war chest, and a novel drug pipeline, Damora Therapeutics is making an aggressive play to redefine blood cancer treatment.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

Fueled by personal tragedy and backed by tech titans, a new foundation aims to revolutionize lung cancer detection using AI and genetics for non-smokers.

As its oesophageal cancer vaccine enters trials, Infinitopes hires a top CSO with a track record of bringing breakthrough therapies to market.

Actuate Therapeutics gets FDA nod for its oral cancer drug elraglusib, shifting strategy to improve patient outcomes and tackle hard-to-treat tumors.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

As Talphera preps its Q1 update, all eyes are on its breakthrough drug Niyad® and the mounting costs of bringing a potential game-changer to market.

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.